Systemic Aspergillosis and Candidiasis Market Emerging Trends Influencing Growth
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Much Growth In Market Value Is Expected For The Systemic Aspergillosis And Systemic Candidiasis Market Between 2026 And 2030?
The systemic aspergillosis and systemic candidiasis market size has seen consistent expansion in recent years. It is projected to grow from $7.57 billion in 2025 to $7.94 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 4.9%. The market’s historical growth can be attributed to several factors, including an increasing number of immunocompromised patient populations, the rising prevalence of invasive fungal infections, the availability of azole and amphotericin formulations, the expansion of hospital intensive care units, and improved diagnostic awareness.
The market size for systemic aspergillosis and systemic candidiasis is projected to experience robust expansion in the coming years. It is anticipated to grow to $9.76 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 5.3%. This growth during the forecast period can be attributed to the increasing development of novel antifungal agents, a rising focus on antifungal resistance management, the expansion of targeted antifungal therapies, growing investments in infectious disease research, and the increasing adoption of combination treatment regimens. Major trends expected in the forecast period include a greater embrace of advanced antifungal therapies, an increased emphasis on the early diagnosis of systemic fungal infections, the broader implementation of combination antifungal treatment approaches, a growing demand for hospital-based critical care antifungals, and enhanced monitoring of drug resistance patterns.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12148&type=smp
What Key Drivers Are Fueling The Growth Of The Systemic Aspergillosis And Systemic Candidiasis Market?
The market for systemic aspergillosis and systemic candidiasis is anticipated to expand due to the rising occurrence of fungal diseases going forward. These diseases are defined as infections stemming from fungi, capable of impacting diverse areas of the body and leading to various symptoms and complications. Examples of such diseases encompass cutaneous skin infections, respiratory infections, and systemic infections. Treatment for fungal diseases involves antifungal medications, including oral azoles, voriconazole, and liposomal amphotericin B. For instance, in 2023, according to the Uk Health Security Agency, a UK-based government agency, in 2023, the rate of yeast-related bloodstream infections across England rose by 4% compared to 2022. Consequently, the rising prevalence of fungal disease is fueling the expansion of the systemic aspergillosis and systemic candidiasis market.
What Are The Main Segments Within The Systemic Aspergillosis And Systemic Candidiasis Market Segment Structure?
The systemic aspergillosis and systemic candidiasis market covered in this report is segmented –
1) By Type: Systemic Oral Azoles, Voriconazole, Liposomal Amphotericin B, Topical Antifungal Agents, Other Types
2) By Application: Allergic Bronchopulmonary Aspergillosis (ABPA), Chronic Pulmonary Aspergillosis (CPA), Gastrointestinal Candidiasis, Genitourinary Tract Candidiasis, Other Applications
3) By End User: Clinic, Hospital, Other End Users
Subsegments:
1) By Systemic Oral Azoles: Fluconazole, Itraconazole, Posaconazole, Voriconazole
2) By Voriconazole: Voriconazole Tablets, Voriconazole Injection
3) By Liposomal Amphotericin B: Liposomal Amphotericin B For Systemic Aspergillosis, Liposomal Amphotericin B For Systemic Candidiasis
4) By Topical Antifungal Agents: Topical Azoles, Topical Polyenes, Topical Allylamines
5) By Other Types: Echinocandins, Antifungal Combination Therapies, Other Emerging Antifungal Agents
What Trends Are Influencing The Systemic Aspergillosis And Systemic Candidiasis Market?
Leading companies active in the systemic aspergillosis and systemic candidiasis markets are prioritizing the development of advanced products, such as echinocandins, to boost treatment efficacy and address the growing concerns of antifungal resistance. Echinocandins are a class of antifungal medicines that hinder the synthesis of β-glucan, a fundamental component of the fungal cell wall. For instance, in March 2023, Cidara Therapeutics, a US-based biotechnology company, and Melinta Therapeutics, a US-based biotechnology company, obtained approval from the Food and Drug Administration (FDA), a US-based federal agency for protecting public health, for REZZAYO (rezafungin for injection). REZZAYO (rezafungin for injection) is a novel once-weekly echinocandin intended for the treatment of candidemia in adults who have limited or no alternative therapeutic options. Designed for straightforward administration, REZZAYO’s once-weekly dosing regimen streamlines treatment and enhances the continuity of care for patients with invasive candidiasis. It proves especially beneficial for individuals in hospital settings, where the effective management of such infections is vital.
Who Are The Companies Participating In The Systemic Aspergillosis And Systemic Candidiasis Market?
Major companies operating in the systemic aspergillosis and systemic candidiasis market are Pfizer Inc, Merck & Co. Inc, AbbVie Inc, Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Abbott Laboratories, Sanofi S.A, GlaxoSmithKline PLC, Gilead Sciences Inc, Astellas Pharma Inc, Matinas BioPharma Holdings Inc, Shionogi & Co. Ltd, Cipla Limited, Basilea Pharmaceutica Ltd, Cidara Therapeutics Inc, Entasis Therapeutics Inc, F2G Ltd, Mycovia Pharmaceuticals Inc, ContraFect Corporation, Enzon Pharmaceutical Inc, Pacgen Life Science Corporation, Biosergen AS
Get The Full Systemic Aspergillosis And Systemic Candidiasis Market Report:
Which Region Dominates The Systemic Aspergillosis And Systemic Candidiasis Market By Market Share?
North America was the largest region in the systemic aspergillosis and systemic candidiasis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the systemic aspergillosis and systemic candidiasis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Systemic Aspergillosis And Systemic Candidiasis Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Systemic Aspergillosis And Systemic Candidiasis Market 2026, By The Business Research Company
Aspergillosis Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/aspergillosis-treatment-global-market-report
Candidiasis Therapeutics Market Report
https://www.thebusinessresearchcompany.com/report/candidiasis-therapeutics-global-market-report
Invasive Fungal Infections Market Report
https://www.thebusinessresearchcompany.com/report/invasive-fungal-infections-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
